Parameter | No DSS | DSS+HuIgG | DSS+IL-18bp |
---|---|---|---|
IL-18bp.Fc treatment inhibited ulceration and inflammation in the large intestine associated with DSS colitis. C57BL/6 mice were given 2% DSS in water from day 0 to day 7. Groups of mice received 600 μg/day IL-18bp.Fc or control human IgG (HuIgG) from day 0 to day 7. Mice were sacrificed on day 8 and histopathological analysis performed. | |||
*p<0.05, **p<0.01, ***p<0.001 for the DSS+IL-18bp.Fc group compared with the DSS+HuIgG treated group (n=6/group). | |||
Increased lymphocytes | 0 | 3.5 (0.54) | 2.33 (1.21)* |
Increased neutrophils | 0 | 2.83 (0.98) | 1.33 (0.81)** |
Ulceration | 0 | 3.5 (0.55) | 1 (0.89)*** |
Oedema | 0 | 3.5 (0.54) | 1.33 (0.8)*** |
Crypt degeneration | 0 | 2.7 (1) | 1.5 (1.7)ns |
Crypt regeneration | 0 | 3 (0.8) | 1.2 (0.9)** |
Crypt length | 216.7 (25.8) | 416.7 (75.3) | 283.3 (98.3)* |
No of ulcers | 0 | 3.8 (0.7) | 0.83 (0.75)*** |
Average total lesion score | 0 | 19.3 | 9.2 |